Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
Open Access
- 1 September 2020
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 9679-9688
Abstract
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the crossroad to the B-cell receptor and cytokine receptor which play a key role in CLL cell survival, proliferation and migration. Idelalisib is the first in class PI3Kδ inhibitor approved for the treatment of relapsed/refractory CLL in combination with rituximab. Idelalisib activity in heavily treated patients is balanced by recurrent adverse events which limit its long-term use. These limitations prompt the investigation on novel PI3K inhibitors, also targeting different protein isoforms, and alternative schedule strategies. In this regard, duvelisib is the only PI3K γ and δ inhibitor approved as single agent for relapsed CLL. In this review, we will address novel insights on PI3K structure, isoforms, regulating signaling and the most updated data of next-generation PI3K inhibitors in CLL.Keywords
This publication has 68 references indexed in Scilit:
- p85α SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular StarvationMolecular Cell, 2012
- Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85α Src homology-2 domainsProceedings of the National Academy of Sciences, 2011
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBlood, 2011
- Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachBlood, 2009
- Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomasBlood, 2004
- Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase CδBlood, 2002
- Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-KinaseJournal of Biological Chemistry, 2001
- Modification of Phosphatidylinositol 3-Kinase SH2 Domain Binding Properties by Abl- or Lck-mediated Tyrosine Phosphorylation at Tyr-688Journal of Biological Chemistry, 1998
- Activation of Phosphatidylinositol-3′ Kinase by Src-Family Kinase SH3 Binding to the p85 SubunitScience, 1994